Compare Twist Bioscience Corp (TWST) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Verisign, Inc. — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.26B), while Verisign, Inc. trades at $287 (market cap $25.94B). The key difference: Verisign, Inc. is far larger — about 3.1× Twist Bioscience Corp's market cap, and Verisign, Inc. pays a 1.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | VRSN | |
|---|---|---|
Market Cap | $8.26B | $25.94B |
Sector | Health | Technology |
52-Week High | $153.10 | $310.00 |
52-Week Low | $24.16 | $211.49 |
Enterprise Value | $8.18B | $27.25B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal despite strong institutional buying interest. The company maintains exceptional profitability with 49.77% net margins and consistent revenue growth, though recent earnings have been mixed with two misses in the last four quarters. A major antitrust lawsuit filed in September 2026 poses significant regulatory risk, while analyst consensus remains bullish with a $328.50 price target representing 16% upside potential.
The stock presents a compelling value proposition given its strong cash flow generation and dominant market position in domain registry services, but faces headwinds from legal challenges and competitive pressures. Current valuation at 30.64 P/E appears reasonable for the quality of earnings, though the negative shareholder equity position warrants monitoring of debt levels. Upside potential exists if the company successfully navigates regulatory challenges and maintains its pricing power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
